Using mRNA nanoparticles to help the immune system treat Type 1 diabetes
Tolerance-Inducing mRNA Nanoparticles to Treat Type 1 Diabetes
This study is exploring a new treatment for Type 1 diabetes that uses tiny particles to help your immune system learn how to protect insulin-producing cells in your pancreas, which could help keep your diabetes from getting worse.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10908728 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy for Type 1 diabetes (T1D) by using mRNA nanoparticles to modify the immune system. The approach involves genetically engineering antigen-presenting cells in the liver to present specific autoantigens associated with T1D, which may help the body develop protective regulatory T cells. By creating biodegradable nanoparticles, the researchers aim to safely program these immune cells in vivo, potentially preventing the progression of the disease and protecting insulin-producing cells in the pancreas.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 diabetes, particularly those in the early stages of the disease.
Not a fit: Patients with Type 2 diabetes or those who have advanced Type 1 diabetes with significant complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a transformative therapy that prevents or slows the progression of Type 1 diabetes.
How similar studies have performed: While the approach of using mRNA nanoparticles for immune modulation is relatively novel, similar strategies in other autoimmune diseases have shown promising results.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Green, Jordan — Johns Hopkins University
- Study coordinator: Green, Jordan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.